Arrowhead Research Corp (ARWR) 11.00 $ARWR
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Top Gainers on the Move -- Research on Arrowhead Research, Endocyte, Ambac Financial, and ZIOPHARM Oncology
PR Newswire - Wed Apr 23, 11:40AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at:
Arrowhead Research Shares Down 29.9% Since SmarTrend's Sell Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 23, 10:57AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 1 month, Arrowhead Research has returned 29.86% as of today's recent price of $13.00.
35.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 16, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 3 weeks, Arrowhead Research has returned 35.34% as of today's recent price of $11.99.
Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Apr 16, 8:47AM CDT
Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate
SmarTrend Watching for Potential Rebound in Shares of Arrowhead Research After 4.87% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:45PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $12.32 to a high of $13.76. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $12.84 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Arrowhead Research (ARWR) Stock is Down Today
at The Street - Mon Apr 14, 2:00PM CDT
Arrowhead Research (ARWR) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering...
Downtrend Call Working As Arrowhead Research Stock Falls 10.2% (ARWR)
Comtex SmarTrend(R) - Wed Apr 09, 9:20AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 weeks, Arrowhead Research has returned 10.17% as of today's recent price of $16.65.
A $1 Trillion Drug Market?
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 07, 5:30PM CDT
At the Barclays Global Healthcare Conference 2014 last month, Christopher Anzalone, president and CEO of Arrowhead Research put up a slide suggesting that its hepatitis B drug would treat a $1 trillion market "even under conservative pricing...
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Top Gainers under the Scanner -- Research on Trina Solar, JA Solar, Arrowhead Research, and King Digital Entertainment
PR Newswire - Wed Apr 02, 8:59AM CDT
The US markets saw a positive sentiment on Tuesday, April 01, 2014, with the NASDAQ Composite closing at 4,268.04, up 1.64%, the Dow Jones Industrial Average ending the session at 16,532.61, up 0.46% and the S&P 500 edging 0.70% higher to finish the trading session at 1,885.52. The session saw a positive impact from Consumer Discretionary, Information Technology and Industrials sectors along with a drag from Utilities, and Consumer Staples sectors. A number of stocks saw large movements, including Trina Solar Ltd (NYSE: TSL), JA Solar Holdings Co. Ltd (NASDAQ: JASO), Arrowhead Research Corp. (NASDAQ: ARWR) and King Digital Entertainment PLC (NYSE: KING). Free technical research on TSL, JASO, ARWR and KING can be downloaded upon signing up at:
Why Arrowhead Research Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 01, 12:36PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Arrowhead Research , a clinical-stage...
Why Arrowhead Research (ARWR) Stock Is Up Today
at The Street - Tue Apr 01, 10:24AM CDT
Arrowhead Research (ARWR) is up 12% to $18.41 in trading Tuesday
Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
Business Wire - Tue Apr 01, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter.
3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos
George Budwell, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
By all accounts, biotech has had a rough week. The iShares Nasdaq Biotechnology Index is down more than 8%, and concerns over a bubble abound. Yet some companies are falling much faster than the broader sector. Are these companies becoming value...
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Top Gainers on the Move -- Research on Arrowhead Research, Endocyte, Ambac Financial, and ZIOPHARM Oncology
PR Newswire - Wed Apr 23, 11:40AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at:
Arrowhead Research Shares Down 29.9% Since SmarTrend's Sell Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 23, 10:57AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 1 month, Arrowhead Research has returned 29.86% as of today's recent price of $13.00.
35.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 16, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 3 weeks, Arrowhead Research has returned 35.34% as of today's recent price of $11.99.
Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Apr 16, 8:47AM CDT
Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate
SmarTrend Watching for Potential Rebound in Shares of Arrowhead Research After 4.87% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:45PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $12.32 to a high of $13.76. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $12.84 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Arrowhead Research (ARWR) Stock is Down Today
at The Street - Mon Apr 14, 2:00PM CDT
Arrowhead Research (ARWR) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering...
Downtrend Call Working As Arrowhead Research Stock Falls 10.2% (ARWR)
Comtex SmarTrend(R) - Wed Apr 09, 9:20AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 weeks, Arrowhead Research has returned 10.17% as of today's recent price of $16.65.
A $1 Trillion Drug Market?
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 07, 5:30PM CDT
At the Barclays Global Healthcare Conference 2014 last month, Christopher Anzalone, president and CEO of Arrowhead Research put up a slide suggesting that its hepatitis B drug would treat a $1 trillion market "even under conservative pricing...
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Top Gainers under the Scanner -- Research on Trina Solar, JA Solar, Arrowhead Research, and King Digital Entertainment
PR Newswire - Wed Apr 02, 8:59AM CDT
The US markets saw a positive sentiment on Tuesday, April 01, 2014, with the NASDAQ Composite closing at 4,268.04, up 1.64%, the Dow Jones Industrial Average ending the session at 16,532.61, up 0.46% and the S&P 500 edging 0.70% higher to finish the trading session at 1,885.52. The session saw a positive impact from Consumer Discretionary, Information Technology and Industrials sectors along with a drag from Utilities, and Consumer Staples sectors. A number of stocks saw large movements, including Trina Solar Ltd (NYSE: TSL), JA Solar Holdings Co. Ltd (NASDAQ: JASO), Arrowhead Research Corp. (NASDAQ: ARWR) and King Digital Entertainment PLC (NYSE: KING). Free technical research on TSL, JASO, ARWR and KING can be downloaded upon signing up at:
Why Arrowhead Research Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 01, 12:36PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Arrowhead Research , a clinical-stage...
Why Arrowhead Research (ARWR) Stock Is Up Today
at The Street - Tue Apr 01, 10:24AM CDT
Arrowhead Research (ARWR) is up 12% to $18.41 in trading Tuesday
Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
Business Wire - Tue Apr 01, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter.
3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos
George Budwell, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
By all accounts, biotech has had a rough week. The iShares Nasdaq Biotechnology Index is down more than 8%, and concerns over a bubble abound. Yet some companies are falling much faster than the broader sector. Are these companies becoming value...
